Marina Elena Cazzaniga

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology · 2015 · 1.1K citations · Full text

Phase 3, Gastrointestinal Oncology, Medicine +8

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 626 citations · Full text

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

Guido Cavaletti, David R. Cornblath, Ingemar S. J. Merkies et al. · Annals of Oncology · 2012 · 284 citations · Full text

Health Sciences, Peripheral Nerve Injury, Pain Medicine +10

Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer

William C. Dooley, Britt‐Marie Ljung, U. Veronesi et al. · JNCI Journal of the National Cancer Institute · 2001 · 275 citations · Full text

A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers

Andrea DeCensi, C. Robertson, Giuseppe Viale et al. · JNCI Journal of the National Cancer Institute · 2003 · 221 citations · Full text